<DOC>
	<DOC>NCT01407887</DOC>
	<brief_summary>Title: Efficacy and safety of artesunate-amodiaquine combined with methylene blue for falciparum malaria treatment in African children: randomised controlled trial. Design: Mono-centre, two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Phase: Phase II. Objectives: The primary objective of this trial is to study the efficacy and safety of the triple therapy artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) given over three days in young children with uncomplicated falciparum malaria in Burkina Faso compared to the local standard three days artemisinin-based combination therapy (ACT) AS-AQ regimen. Population: Children aged 6-59 months with uncomplicated falciparum malaria from Nouna Hospital in north-western Burkina Faso. Sample size: 180 patients (90 per study arm).</brief_summary>
	<brief_title>Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>659 months old children (male and female) Weight ≥ 6kg Uncomplicated malaria caused by P. falciparum Asexual parasites ≥ 2 000/µl and ≤ 200 000/µl Axillary temperature ≥ 37.5°C or a history of fever during last 24 hours Burkinabe nationality Permanent residence in the study area with no intention of leaving during the surveillance period Informed consent Severe malaria (WHO 2000) Vomiting (3 or more within 24 hours before the visit) Any apparent significant disease, including severe malnutrition A history of a previous, significant adverse reaction to either of the study drugs Anaemia (haemoglobin &lt; 7 g/dl) Treated in the same trial before All modern antimalarial treatment prior to inclusion (last seven days) Simultaneous participation in another investigational study Treatment with other investigational drugs</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>children</keyword>
</DOC>